SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Science 37 Holdings, Inc. (Nasdaq – SNCE)

BALA CYNWYD – January 29, 2024 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Science 37 Holdings, Inc. (“Science 37” or the “Company”) (Nasdaq – SNCE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to eMed, LLC (“eMed”). Under the terms of the agreement, Science 37 stockholders will receive $5.75 in cash for each share of the Company’s stock.

The investigation concerns whether the Science 37 Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether eMed is paying fair value to shareholders of the Company.

If you own shares of Science 37 stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.